UNC-School of Medicine: Researchers Release Results From Clinical Trial for Treatment of Primary Ciliary Dyskinesia
September 13, 2023
September 13, 2023
CHAPEL HILL, North Carolina, Sept. 13 (TNSres) -- The University of North Carolina School of Medicine issued the following news release:
* * *
A phase 2 study, led by Thomas W. Ferkol, MD, at the UNC School of Medicine, demonstrates safety and efficacy of idrevloride with hypertonic saline for treatment of primary ciliary dyskinesia, a rare genetic disorder that can lead to permanent lung damage.
* * *
Primary ciliary dyskenisia (PCD) is a rare . . .
* * *
A phase 2 study, led by Thomas W. Ferkol, MD, at the UNC School of Medicine, demonstrates safety and efficacy of idrevloride with hypertonic saline for treatment of primary ciliary dyskinesia, a rare genetic disorder that can lead to permanent lung damage.
* * *
Primary ciliary dyskenisia (PCD) is a rare . . .